EU/3/20/2287
Table of contents
About
On 4 June 2020, orphan designation EU/3/20/2287 was granted by the European Commission to Raremoon Consulting Limited, United Kingdom, for adeno-associated virus serotype 9 containing the human ASPA gene (also known as BBP-812) for the treatment of Canavan disease.
The sponsorship was transferred to Raremoon Consulting Esp S.L., Spain, in March 2021.
Key facts
Active substance |
Adeno-associated virus serotype 9 containing the human ASPA gene
|
Disease / condition |
Treatment of Canavan disease
|
Date of first decision |
04/06/2020
|
Outcome |
Positive
|
EU designation number |
EU/3/20/2287
|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
Raremoon Consulting Esp S.L.
Ronda De Sant Pere 33 Ppal 3 Y 4
08010 Barcelona
Spain
Tel. +34 518 88 03 22
E-mail: chris@raremoonconsulting.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.